Claims
- 1. A compound of the formula: ##STR19## or a pharmaceutically-acceptable salt, ester, amide or prodrug thereof, wherein
- R.sup.1 is selected from the group consisting of
- (1) hydrogen;
- (2) C.sub.1 -C.sub.6 -alkyl;
- (3) C.sub.6 -C.sub.12 -aryl-C.sub.1 -C.sub.4 -alkyl,;
- (4) substituted C.sub.6 -C.sub.12 -aryl-C.sub.1 -C.sub.4 -alkyl;
- (5) N-protecting group;
- (6) --CO--C.sub.1 -C.sub.6 -alkyl;
- (7) --CO--C.sub.6 -C.sub.12 -aryl;
- (8) --CO-substituted C.sub.6 -C.sub.12 -aryl;
- (9) --CO--C.sub.6 -C.sub.12 -aryl-C.sub.1 -C.sub.4 -alkyl;
- (10) --CO-substituted C.sub.6 -C.sub.12 -aryl-C.sub.1 -C.sub.4 -alkyl; and
- (11) --CO--Het;
- R.sup.2 is hydrogen when R.sup.1 is selected from options (5)-(11) above, or when R.sup.1 is selected from options (1)-(4) above, hydrogen, C.sub.1 -C.sub.6 -alkyl, C.sub.6 -aryl-C.sub.1 -C.sub.4 -alkyl, or substituted C.sub.6 -aryl-C.sub.1 -C.sub.4 -alkyl;
- R.sup.3 is selected from the group consisting of:
- (1) --CO--OR.sup.6, wherein R.sup.6 is hydrogen, C.sub.1 -C.sub.6 -alkyl, C.sub.2 -C.sub.6 -alkenyl, cyclo-C.sub.3 -C.sub.7 -alkyl, C.sub.6 -C.sub.12 -aryl, substituted C.sub.6 -C.sub.12 -aryl, C.sub.6 -C.sub.12 -aryl-C.sub.1 -C.sub.4 -alkyl, or substituted C.sub.6 -C.sub.12 -aryl-C.sub.1 -C.sub.4 -alkyl;
- (2) --CHR.sup.7 --OR.sup.8, wherein R.sup.7 is hydrogen, C.sub.1 -C.sub.6 -alkyl, cyclo-C.sub.3 -C.sub.7 -alkyl, C.sub.2 -C.sub.4 -alkenyl, or C.sub.6 -C.sub.12 -aryl: and R.sup.8 is hydrogen, C.sub.1 -C.sub.6 -alkyl, or an oxygen protecting group; and ##STR20## wherein n is 0-2, and R.sup.7 and R.sup.8 are as defined above; R.sup.4 is hydrogen, C.sub.1 -C.sub.6 -alkyl, C.sub.6 -C.sub.12 -aryl-C.sub.1 -C.sub.3 -alkyl, or substituted C.sub.6 -C.sub.12 -aryl-C.sub.1 -C.sub.3 -alkyl;
- W is selected from
- (a) C.sub.2 -C.sub.4 -alkylene;
- (b) C.sub.2 -C.sub.4 -alkenylene;
- (c) C.sub.2 -C.sub.4 -alkynylene;
- (d) 1,4-(C.sub.5 -C.sub.7 -cycloalkylene);
- (e) 1,4-(C.sub.5 -C.sub.7 -cycloalkenylene);
- (f) phenylene;
- (g) C.sub.1 -C.sub.3 -alkylene-phenylene; and
- (h) phenylene-C.sub.1 -C.sub.3 -alkylene; and
- R.sup.9 and R.sup.10 are independently hydrogen or C.sub.1 -C.sub.6 -alkyl;
- Z is S or NR.sup.11, wherein R.sup.11 is hydrogen, C.sub.1 -C.sub.6 -alkyl, C.sub.6 -C.sub.12 -aryl-C.sub.1 -C.sub.4 -alkyl or substituted C.sub.6 -C.sub.12 -aryl-C.sub.1 -C.sub.4 -alkyl; and
- R.sup.5 is ##STR21## wherein G is either nitro or cyano; and R.sup.S, which may be substituted at one or two or positions 3-, 5- or 6-, represents one or two substituents independently selected from the group consisting of:
- (a) halogen;
- (b) C.sub.1 -C.sub.4 -alkyl;
- (c) C.sub.1 -C.sub.4 -alkoxy;
- (d) C.sub.1 -C.sub.4 -thioalkoxy;
- (e) hydroxy;
- (f) carbo-C.sub.1 -C.sub.4 -alkoxy;
- (g) cyano; and
- (h) halo-C.sub.1 -C.sub.4 -alkyl; or ##STR22## wherein G and R.sup.S are as defined above, and J and K taken together with the existing ring represent a fused bi- or tricyclic carbocycle of from 9-14 carbon atoms, wherein R.sup.S may be substituted anywhere within the entire bi- or tricyclic ring system except the 4-position.
- 2. A compound according to claim 1, wherein R.sup.1 is hydrogen or an N-protecting group, R.sup.2 is hydrogen, R.sup.4 is hydrogen, R.sup.5 is selected from option (1), wherein G is NO.sub.2 and R.sup.S is one substituent as defined in claim 1 and is substituted at the 5-position, and R.sup.3, R.sup.9, R.sup.10 and Z are as defined in claim 1.
- 3. A compound according to claim 1, which is:
- (2S)-2-Amino-5-(5-methyl-2-nitrophenylamino)pentanoic acid;
- (2S)-2-Amino-5-(5-methyl-2-nitrophenylamino)-pent-3E-en-1-ol;
- 2-Amino-5-(5-methyl-2-nitrophenylamino)-1-pentanol;
- (2S)-2-Amino-5-(5-hydroxy-2-nitrophenylamino)pentanoic acid;
- (2S)-2-Amino-5-(5-methoxy-2-nitrophenylamino)pentanoic acid;
- (2S)-2-Amino-5-(2-chloro-6-nitrophenylamino)pentanoic acid;
- (2S)-2-Amino-6-(2-nitro-5-methylphenylamino)hexanoic acid;
- (2S)-2-Amino-5-(5-methyl-2-nitrophenylthioxy)pentanoic acid;
- (2R)-2-(N-(1,1-Dimethylethoxycarbonyl)amino)-5-(5-methyl-2-nitrophenylamino)pentanoic acid;
- (2R)-2-Amino-5-(5-methyl-2-nitrophenylamino)pentanoic acid;
- 2-Amino-4-(5-methyl-2-nitrophenylamino)butanoic acid;
- (2S)-2-Amino-6-(2-nitrophenyamino)hexanoic acid;
- (2S)-2-(Benzyloxycarbonylamino)-5-(5-methyl-2-nitrophenoxy)pentanoic acid t-butyl ester;
- (2S)-3-[2-(2-Nitro-5-methylphenylamino)ethylthioxy]propanoic acid;
- N.sup.2 -Boc-2-amino-5-(5-methyl-2-nitrophenylamino)-1-phenyl-1-pentanol;
- N.sup.3 -Boc-3-amino-6-(5-methyl-2-nitrophenylamino)-2-phenyl-2-hexanol;
- 2(S)-Amino-5-(5-methyl-2-nitrophenylthioxy)pentanol;
- N.sup.2 -Hexanoyl-(2S)-2-amino-5-(5-methyl-2-nitrophenylamino)pentanoic acid;
- N.sup.2 -Hexanoyl-(2S)-2-amino-5-(5-methyl-2-nitrophenylthioxy)pentanoic acid;
- 2-Amino-5-(5-methyl-2-nitrophenylamino)-1-phenyl-1-pentanol;
- 3-Amino-6-(5-methyl-2-nitrophenylamino)-2-phenyl-2-hexanol;
- 4-(5-Methyl-2-nitrophenylamino)phenyl-(S)-glycine;
- N.sup.2 -Benzoyl-2(S)-amino-5-(5-methyl-2-nitrophenylamino)pentanoic acid;
- N.sup.2 -Acetyl-2(S)-amino-5-(5-methyl-2-nitrophenylamino)pentanoic acid;
- N.sup.2 -Phenylacetyl-2(S)-amino-5-(5-methyl-2-nitrophenylamino)pentanoic acid;
- N.sup.2 -Trifluoroacetyl-2(S)-amino-5-(5-methyl-2-nitrophenylamino)pentanoic acid;
- N.sup.2 -(4-Phenyl-2E-butenoyl)-2(S)-amino-5-(5-methyl-2-nitrophenylamino)pentanoic acid;
- N.sup.2 -(2E-Butenoyl)-2(S)-amino-5-(5-methyl-2-nitrophenylamino)pentanoic acid;
- N.sup.2 -(2-Methylpropanoyl)-2 (S)-amino-5-(5-methyl-2-nitrophenylamino)pentanoic acid;
- N.sup.2 -(2-Furoyl)-2(S)-amino-5-(5-methyl-2-nitrophenylamino)pentanoic acid;
- N.sup.2 -(Cyclohexanecarbonyl)-2(S)-amino-5-(5-( methyl-2-nitrophenylamino)pentanoic acid;
- N.sup.2 -(Thiopheneacetyl)-2(S)-amino-5-(5-methyl-2-nitrophenylamino)pentanoic acid;
- N.sup.2 -(Cyclopropanecarbonyl)-2 (S)-amino-5-(5-(methyl-2-nitrophenylamino)pentanoic acid;
- N.sup.2 -Benzoyl-2(S)-amino-5-(5-methyl-2-nitrophenylthioxy)pentanoic acid;
- N.sup.2 -Acetyl-2(S)-amino-5-(5-methyl-2-nitrophenylthioxy)pentanoic acid;
- N.sup.2 -Phenylacetyl-2(S )-amino-5-(5-methyl-2-nitrophenylthioxy)pentanoic acid;
- N.sup.2 -Trifluoroacetyl-2(S)-amino-5-(5-methyl-2-nitrophenylthioxy)pentanoic acid;
- N.sup.2 -(4-Phenyl-2E-butenoyl)-2(S)-2-amino-5-(5-methyl-2-nitrophenylthioxy)pentanoic acid;
- N.sup.2 -(2E-Butenoyl)-2(S)-amino-5-(5-methyl-2-nitrophenylthioxy)pentanoic acid;
- N.sup.2 -(2-Methylpropanoyl)-2(S )-amino-5-(5-methyl-2-nitrophenylthioxy)pentanoic acid;
- N.sup.2 -(2-Furoyl)-2(S)-amino-5-(5-methyl-2-nitrophenylthioxy)pentanoic acid;
- N.sup.2 -(Cyclohexanecarbonyl)-2(S)-amino-5-(5-methyl-2-nitrophenylthioxy)pentanoic acid;
- N.sup.2 -(Thiopheneacetyl)-2(S)-amino-5-(5-methyl-2-nitrophenylthioxy)pentanoic acid;
- N.sup.2 -(Cyclopropanecarbonyl)-2(S)-amino-5-(5-methyl-2-nitrophenylthioxy)pentanoic acid;
- 3-Amino-6-(5-methyl-2-nitrophenylamino)-2-hexanol;
- 4-Amino-7-(5-methyl-2-nitrophenylamino)-1-hepten-3-ol;
- 4-Amino-7-(5-methyl-2-nitrophenylamino)-3-heptanol;
- 5-Amino-8-(5-methyl-2-nitrophenylamino)-2-methyl-4-octanol;
- 5-Amino-8-(5-methyl-2-nitrophenylamino)-1-octen-4-ol;
- 6-Amino-9-(5-methyl-2-nitrophenylamino)-5-nonanol;
- 2-Amino-5-(5-methyl-2-nitrophenylamino)-1-phenyl-1-pentanol;
- 2-Amino-5-(5-methyl-2-nitrophenylamino)-1-(2'-thienyl)-1-pentanol;
- 2-Amino-5-(5-methyl-2-nitrophenylamino)-1-(cyclopentyl)-1-pentanol;
- 2-Amino-5-(5-methyl-2-nitrophenylamino)-1-(cyclohexyl)-1-pentanol;
- (2S)-Amino-5-(2-nitro-5-bromonaphthylamino)-pent-3E-enol;
- (2S)-Amino-5-(6-nitro-2,3-dimethyl-phenylamino)-pent-3E-enol;
- (2S)-Amino-5-(2-nitro-5-chloro-phenylamino)-pent-3E-enol;
- (2S)-Amino-5-(2-nitro-6-methyl-phenylamino)-pent-3E-enol;
- (2S)-Amino-5-(2-nitro-3-methyl-phenylamino)-pent-3E-enol;
- (2S)-Amino-5-(2-nitro-5-fluoro-phenylamino)-pent-3E-enol;
- (2S)-Amino-5-(2-nitro-6-chloro-phenylamino)-pent-3E-enol;
- (2S)-Amino-5-(2-nitro-5-chloro-phenylamino)-pent-3E-enol;
- (2S)-Amino-5-(6-nitro-2,3-dichloro-phenylamino)-pent-3E-enol;
- (2S)-Amino-5-(2-nitro-5-hydroxy-phenylamino)-pent-3E-enol;
- (2S)-Amino-5-(2-nitro-5-chloro-6-methylphenylamino)-pent-3E-enol;
- (2S)-Amino-5-(2-nitro-5-fluoro-phenylamino)-pent-3E-enol;
- (2S)-Amino-5-(2-nitro-6-chloro-phenylamino)-pent-3E-enol;
- (2S)-Amino-5-(2-nitro-5-chloro-phenylamino)-pent-3E-enol;
- (2S)-Amino-5-(6-nitro-2,3-dichloro-phenylamino)-pent-3E-enol;
- (2S)-Amino-5-(2-nitro-5-hydroxy-phenylamino)-pent-3E-enol;
- (2S)-Amino-5-(2-nitro-5-chloro-6-methylphenylamino)-pent-3E-enol;
- (2S)-Amino-5-(2-nitro-5-bromo-naphthylamino)pentanoic acid; or
- (2S)-Amino-5-(2-nitro-5-cyano-naphthylamino)pentanoic acid.
- 4. A compound according to claim 3, which is
- (2S)-2-Amino-5-(5-methyl-2-nitrophenylamino)pentanoic acid;
- 2-Amino-5-(5-methyl-2-nitrophenylamino)-pent-3E-en-1-ol;
- 2-Amino-5-(5-methyl-2-nitrophenylamino)-1-pentanol;
- (2S)-2-Amino-5-(5-methyl-2-nitrophenylthioxy)pentanoic acid;
- N.sup.2 -Boc-2-amino-5-(5-methyl-2-nitrophenylamino)-1-phenyl-1-pentanol; or
- N.sup.3 -Boc-3-amino-6-(5-methyl-2-nitrophenylamino)-2-phenyl-2-hexanol.
- 5. A pharmaceutical composition for treating disorders of the vascular system or diseases of the cartilage characterized by the regulation of soluble guanylate cyclase or nitric oxide synthase activity, comprising a pharmaceutically-acceptable carrier and a therapeutically-effective amount of a compound according to claim 1.
- 6. A method for selectively-regulating soluble guanylate cyclase or nitric oxide synthase activity comprising administering to a patient in need of such treatment a therapeutically-effective amount of a compound according to claim 1.
- 7. A method for treating hypotension, hypertension, coronary vasospasm, cerebral vasoconstriction, cardiomyopathy, atherogenesis, atherosclerosis, myocardial ischemia, cerebral ischemia, diabetes, endotoxemia, sepsis, asthma, rhinitis, synovitis, chondroarthritis or osteoarthritis, comprising administering to a patient in need of such treatment a therapeutically-effective amount of a compound according to claim 1.
- 8. A method for treating disorders of the vascular system or diseases of the cartilage characterized by the regulation of soluble guanylate cyclase or nitric oxide synthase activity, comprising administering a pharmaceutically-acceptable carrier containing a therapeutically-effective amount of 2-amino-5-(2-nitrophenoxy)valeric acid.
CROSS REFERENCE TO OTHER RELATED APPLICATIONS
This application is a continuation-in-part of copending U.S. patent application Ser. No. 07/981,585, filed Nov. 25, 1992, now abandoned.
Non-Patent Literature Citations (2)
Entry |
Kooistra et al, Biochemistry, vol. 17(1978) pp. 345-351. |
Gagnon et al, Can. J. Chem., vol. 30(1952) pp. 592-597. |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
981585 |
Nov 1992 |
|